A TAMO study evaluates the #costeffectiveness of #belzutifan vs everolimus for previously treated advanced ccRCC. At current pricing, belzutifan is unlikely to be cost‑effective in the US or China, highlighting the role of pricing in access.
buff.ly/CxCmOzE
#Oncology #RCC #HealthEconomics

Promising news from #GU26: Research led by @drchoueiri.bsky.social shows that adding #belzutifan to pembrolizumab adjuvant therapy prevented #ccRCC recurrence in high-risk patients better than pembrolizumab alone.

Learn more: https://bit.ly/3OxZdIE

Breaking news for people whose #KidneyCancer was not controlled by immunotherapy: Research led by Dr. Robert Motzer at #GU26 shows that #belzutifan + lenvatinib slows #ccRCC growth longer than cabozantinib.

Learn more: https://bit.ly/4aUKJtW

Belzutifan has demonstrated clinical activity across treatment lines in clear cell RCC.
Evidence supports its use as both front‑ and later‑line therapy, including in combination with TKIs.
🔗 Full article: buff.ly/joEgxsx
#RCC #KidneyCancer #Belzutifan

FDA Approves Belzutifan (Welireg) for Advanced Pheochromocytoma and Paraganglioma: Results of LITESPARK-015 Trial - OncoDaily FDA approves belzutifan (Welireg) as first oral therapy for advanced pheochromocytoma and paraganglioma, based on LITESPARK-015 trial results.

FDA Approves Belzutifan (Welireg) for Advanced Pheochromocytoma and Paraganglioma: Results of LITESPARK-015 Trial
@fda.gov

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Belzutifan #Welireg #Pheochromocytoma #Paraganglioma #LITESPARK-015

LITESPARK-004 phase 2 trial reports that, after 50 months of follow-up, HIF-2α inhibitor belzutifan demonstrated durable responses in #VHL disease-associated tumors

@thelancetoncol.bsky.social @kidneycan.bsky.social

#Onco404 #Cancer #Kanser #Belzutifan #ClinicalTrials #TargetedTherapy #MedSky

The OncoAlert 🚨 VJ Oncology Journal Club

Covering: LITESPARK-005 out on Lancet Oncology :
thelancet.com/journals/lan...

Dr. Rini 🇺🇸 Dr. Powles 🇬🇧of Uromigos discuss #Health-related quality of life with #belzutifan 🆚 #everolimus for advanced #renalcellcarcinoma

Breaking down the latest in #oncology, every week🚨🗞️ @oncoalert.bsky.social

This week Brian Rini & Tom Powles will be discussing LITESPARK-005: #Health-related quality of life with #belzutifan vs #everolimus for advanced #renalcellcarcinoma

Look out for episode tomorrow

👉https://lnkd.in/e6kJyPMz

Nierenzellkarzinom: Daten zur Lebensqualität unter HIF-Inhibition vorgelegt Seit wenigen Wochen ist mit Belzutifan eine neue Wirkstoffklasse beim fortgeschrittenen klarzelligen Nierenzellkarzinom in der EU zugelassen. Frisch publizierte Ergebnisse zur Lebensqualität erweitern jetzt die Datenbasis zur Risiko-Nutzen-Bewertung für den HIF-2α-Inhibitor.

Seit wenigen Wochen ist mit #Belzutifan eine neue Wirkstoffklasse beim fortgeschrittenen klarzelligen #Nierenzellkarzinom in der EU zugelassen. Frisch publizierte Ergebnisse zur Lebensqualität erweitern jetzt die Datenbasis zur Risiko-Nutzen-Bewertung für den HIF-2α-Inhibitor. #Medizin #MedSky

Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial Belzutifan for advanced renal cell carcinoma was associated with improved disease-specific symptoms and QOL compared with everolimus. Taken together with the efficacy and safety data from LITESPARK-00...

Online first: Health-related quality of life with #belzutifan versus #everolimus for advanced #RenalCellCarcinoma #LITESPARK005: patient-reported outcomes from a randomised, open-label, phase 3 trial

www.thelancet.com/journals/lan...

Pediatric patients with von Hippel–Lindau and hemangioblastomas treated successfully with belzutifan Hemangioblastoma is the most common tumor associated with von Hippel–Lindau (VHL), and are a leading cause of mortality. We present five pediatric patients with VHL-associated hemangioblastomas treat...

Delivering on the promise of #PrecisionOncology for kids with #VonHippelLindau treating with Hif2a inhibitor #Belzutifan

onlinelibrary.wiley.com/doi/10.1002/...

#pembro #belzutifan #MK-6482 #Chemo